TY - JOUR
KW - opioid abuse
KW - buprenorphine
KW - Health Policy
KW - access to care
KW - Self-treatment
KW - Literature Review
KW - Human
KW - Public Health
KW - Treatment Barriers
KW - Motivation
KW - Substance use disorder
KW - Opiates
KW - Drug Withdrawal
KW - Treatment Effectiveness Evaluation
KW - article
KW - 3233:Substance Abuse & Addiction
AU - Howard D. Chilcoat
AU - Halle R. Amick
AU - Molly R. Sherwood
AU - Kelly E. Dunn
A1 - 
AD - Indivior PLC, North Chesterfield, VA, US howard.chilcoat@indivior.com; Venebio Group, LLC, Richmond, VA, US halle.amick@venebio.com molly.sherwood@venebio.com; Johns Hopkins University School of Medicine, Baltimore, MD, US kdunn9@jhmi.edu; Chilcoat, Howard D.,10710 Midlothian Turnpike, Suite 125,North Chesterfield,US,23235,Indivior PLC,howard.chilcoat@indivior.com
BT - Journal of substance abuse treatment
C5 - Healthcare Disparities; Opioids & Substance Use
DO - 10.1016/j.jsat.2019.07.005
JF - Journal of substance abuse treatment
LA - English
M1 - Journal Article
PB - Elsevier Science
PY - 2019
SN - 0740-5472, 0740-5472
SP - 148
EP - 157
EP - 
T1 - Buprenorphine in the United States: Motives for abuse, misuse, and diversion
T2 - Journal of substance abuse treatment
TI - Buprenorphine in the United States: Motives for abuse, misuse, and diversion
U1 - Healthcare Disparities; Opioids & Substance Use
U3 - 10.1016/j.jsat.2019.07.005
VL - 104
VO - 0740-5472, 0740-5472
Y1 - 2019
Y2 - 09
ER -